A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients.

Trial Profile

A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Fluorouracil; Folic acid; Folinic acid
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 22 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 09 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top